Core Viewpoint - The report by Liao Asset on Health Road (2587.HK) initiates coverage with a "Buy" rating and a target price of HKD 68.5, indicating a potential upside of 218% from the current price [1] Company Overview - Health Road is a leading full-cycle digital health service platform in China, expanding its enterprise services and digital marketing [1] - The company has established a comprehensive network connecting 2.06 million registered users, 889,000 registered doctors, and 11,762 hospitals, including 1,499 top-tier hospitals [2] - The company’s business model covers the entire healthcare cycle from prevention to management, creating a competitive moat [2] Market Potential - The digital health service market is projected to grow from CNY 113.8 billion in 2024 to CNY 432 billion by 2027, with a compound annual growth rate (CAGR) of 39.10% [1] - By 2030, the market is expected to reach CNY 1 trillion, with a CAGR of 30.30% from 2027 to 2030 [1] Financial Projections - Revenue projections for Health Road from 2025 to 2027 are CNY 2.163 billion, CNY 2.883 billion, and CNY 3.783 billion, with growth rates of 80.10%, 33.29%, and 31.22% respectively [3] - Net profit estimates for the same period are CNY -0.103 billion, CNY 0.135 billion, and CNY 0.332 billion, with growth rates of 61.57%, 231.07%, and 145.93% respectively [3] Competitive Advantages - The company benefits from a stable shareholding structure, with significant stakes held by state-owned and industrial capital, including Baidu at 12.1% and other state-owned entities [2] - The management team possesses strong industry experience and operational capabilities, contributing to improved profitability and decreasing expense ratios [2]
【券商聚焦】丽奥资产给予健康之路(2587.HK)买入评级,目标价68.5港元